Yeast Infections And Candidiasis Sep 3, 2008
This condition, called systemic candidiasis, can be responsible for many different health problems throughout the body. Is Systemic Candidiasis a New Disease ... Systemic candidiasis has probably existed for as long as we've been using antibiotics. (Suite101.com)
Novartis Takes $235 Million Charge After Stopping Trial Aug 29, 2008
Another compound acquired with NeuTec, Mycograb, continues in late-stage trials for the treatment of invasive candidiasis, a life-threatening fungal infection. (Reporting by Sam Cage and Rupert Pretterklieber; Editing by David Cowell). (ABC News -- Wire)
Vaccine Cures Dangerous Yeast Infections in Mice Aug 28, 2008
He said certain hospital procedures, such as gastrointestinal surgery, put people at a higher risk for invasive candidiasis ... If successful, Cutler thinks the vaccine might be used to reduce the risks of invasive candidiasis and might even help prevent vaginal yeast infections. (MEDLINEplus)
Probiotics benefit whole body: Study Aug 26, 2008
They are recommended by doctors and nutritionists, after a course of antibiotics, or as part of the treatment for gut related candidiasis, a fungal infection. There have been claims that probiotics strengthen the immune system to combat allergies, excessive alcohol intake, stress, exposure to toxic substances and other diseases. (Sify.com, India)
Data Show that Abbott's HUMIRA(R) (adalimumab) Reduced the Signs and Symptoms of Ankylosing Spondylitis Up to Three Years Jun 13, 2008
PARIS, June 13 /PRNewswire-FirstCall/ -- Abbott announced new data from the open-label extension of the ATLAS (Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS) phase III clinical trial, which showed HUMIRA(R) (adalimumab) reduced the signs and symptoms of ankylosing spondylitis (AS) for up to three years of treatment among 74 percent of patients tested. AS is a type of arthritis that primarily causes inflammation of the spine and the spinal joints. (PR Newswire)
New Long-Term HUMIRA(R) (adalimumab) Data Show Up to Seven-Year Efficacy with Combination Treatment for Rheumatoid Arthritis Jun 13, 2008
PARIS, June 13 /PRNewswire-FirstCall/ -- Seven-year rheumatoid arthritis (RA) data from open-label extension studies show that treatment with Abbott's HUMIRA(R) (adalimumab) resulted in clinical remission among long-standing RA patients when used in combination with methotrexate (MTX). The percentage of patients achieving clinical remission continued to increase after two or more years of continuous treatment with combination therapy. (PR Newswire)
HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity Jun 13, 2008
Rheumatoid Arthritis is the Leading Cause of Work Disability in Europe PARIS, June 13 /PRNewswire-FirstCall/ -- New data announced today showed that treating patients with early, active rheumatoid arthritis (RA) with Abbott's HUMIRA(R) (adalimumab) and methotrexate (MTX) resulted in an indirect cost savings of euro 4,845 (or approximately USD$6,086 using exchange rates at the time of the study) per patient per year compared to MTX treatment alone. These cost savings were attributed to improved... (PR Newswire)
Al Dente: When physicians and dentists talk May 23, 2008
The lack of saliva opens the door to opportunistic infections, usually candidiasis, which is also known as thrush or yeast infection. Dryness makes dentures slip and uncomfortable to wear. (Malden Observer, MA)
BioAlliance Pharma: Combined Ordinary and Extraordinary General Meeting on April 29th 2008 Mar 21, 2008
The company has launched its first portfolio product (Loramyc) in France and the compound is currently in Phase III clinical development in oropharyngeal candidiasis in the USA. In addition, two other innovative products are currently in Phase III clinical trials: acyclovir Lauriad in oral herpes (based on the same Lauriad muco-adhesive technology as Loramyc, which enables targeted release at the disease site) and doxorubicin Transdrug in primary liver cancer (based on the Transdrug... (BusinessWire)
Barrier Therapeutics Announces Top Management Succession Plan Jan 26, 2008
The first product is currently marketed as Vusion(r), and it is the only product thus far to be approved by the FDA for diaper dermatitis complicated by candidiasis ... 35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis; and Solage(r) (mequinol 2. (Primezone Releases)
FDA Approves Additional Indication for Astellas' MYCAMINE(R) Jan 23, 2008
Jan. 23 /PRNewswire/ -- Astellas Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved their Supplemental New Drug Application (sNDA) seeking approval for the use of MYCAMINE(R) (micafungin sodium) for Injection in the treatment of patients with Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses. MYCAMINE was approved in 2005 for the treatment of patients with esophageal candidiasis and is the only echinocandin approved for the... (PR Newswire)
Glaxo says Advair shows edge over Spiriva in COPD Dec 28, 2007
Candidiasis was also reported more often in the Advair group (6 percent) than the Spiriva group (3 percent). Advair, which is also sold as Seretide, is Glaxo's biggest product, with 2006 sales of 3. (ABC News -- Wire)
Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine Dec 5, 2007
The company has launched its first portfolio product (Loramyc(R)) in France, which is currently in Phase III clinical development in oropharyngeal candidiasis in the USA. In addition, two other innovative products are currently in phase III clinical trials: acyclovir Lauriad(R) in oral herpes (based on the same Lauriad(R) muco-adhesive technology as Loramyc(R), which enables targeted release at the disease site) and doxorubicin Transdrug(R) in primary liver cancer (based on the Transdrug(R)... (PR Newswire)
Barrier Therapeutics Announces Positive Results of Dose Escalation Clinical Safety Study With Pramiconazole Nov 27, 2007
Previously, the Company has also shown positive results in Phase 2a trials with pramiconazole in tinea pedis (athlete's foot), tinea corporis (ring worm), tinea cruris (jock itch), tinea versicolor, vaginal candidiasis and seborrheic dermatitis ... 35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis; and Solage(r) (mequinol 2. (Primezone Releases)
Barrier Therapeutics to Present At the Acumen BioFin Rodman & Renshaw Healthcare Conference On November 6, 2007 Oct 29, 2007
35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis; and Solage(r) (mequinol 2. 0%, tretinoin 0. (Primezone Releases)
Fungal Pneumonia: Opportunistic Oct 14, 2007
Pulmonary Candidiasis, Aspergillosis, Cryptococcosis & Mucormycosis ... Pulmonary Candidiasis. (Suite101.com)
Anidulafungin and Fluconazole for Candidiasis Sep 27, 2007
To the Editor: The study of anidulafungin as compared with fluconazole for invasive candidiasis by Reboli et al. (June 14 issue)1 shows the challenges involved in the design and reporting of noninferiority trials. 2,3 First, the dose of fluconazole may have been inadequate. (New England Journal of Medicine)
Hallucinations not unusual with antifungal therapy Sep 22, 2007
Voriconazole, sold under the trade name Vfend, is a relatively new drug used to treat serious fungus infections, such as invasive mold infections and invasive candidiasis. Many of these patients are extremely ill and are receiving several different drugs, which makes it difficult to distinguish the side effects of specific drugs from the symptoms of the underlying illness. (Scientific American)
BioDelivery Sciences International Sep 11, 2007
Sirgo says he expects the company to add roughly a half-dozen employees as it ratchets up clinical development for the next two drugs in its pipeline: BEMA LA, an acute pain drug, and Bioral Amphotericin B, a treatment for fungal infections that the company thinks will be effective in fighting an esophageal infection called esophageal candidiasis. The company plans to have BEMA LA in phase III trials by the end of 2008, Sirgo says, while Bioral Amphotericin B could enter phase II studies. (Triangle Business Journal)
Anacor Files Registration Statement for Initial Public Offering Sep 1, 2007
In addition, Anacor has a portfolio of other topical product candidates in development for the treatment of psoriasis, gingivitis, acne, vaginal candidiasis and tinea pedis. SOURCE Anacor Pharmaceuticals. (PR Newswire)
Three Studies Suggest Abbott's HUMIRA(R) (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis Jun 15, 2007
One Groundbreaking Study Showed 11 Percent Fewer RA Patients Reported Job Loss When Treated With HUMIRA Combination Therapy Compared to Methotrexate Alone BARCELONA, Spain, June 15 /PRNewswire-FirstCall/ -- Rheumatoid arthritis (RA) is one of the most common causes of disability in the Western world. New data released today show that rheumatoid arthritis (RA) patients treated with Abbott's HUMIRA(R) (adalimumab) stayed working longer, had fewer absences and reported greater improvements in work... (PR Newswire)
Older antifungal still a good choice against tough infections Jun 14, 2007
The first compound used to treat candidiasis (yeast infection) was amphotericin B, which was effective but was limited by side effects ... Although expert guidelines issued in 2004 state that all of the above classes of drugs are appropriate to treat candidiasis, in reality, fluconazole was the one most prescribed ... For the new study, adults with invasive candidiasis were randomly assigned to receive anidulafungin or fluconazole. (Atlanta Journal-Constitution -- Health)
Echinocandins — First-Choice or First-Line Therapy for Invasive Candidiasis? Jun 14, 2007
NEJM -- Echinocandins -- First-Choice or First-Line Therapy for Invasive Candidiasis ... Echinocandins First-Choice or First-Line Therapy for Invasive Candidiasis ... The newest class of antifungal agents was heralded by the approval of caspofungin for candidiasis in 2002, and already. (New England Journal of Medicine)
Anidulafungin versus Fluconazole for Invasive Candidiasis Jun 14, 2007
We compared anidulafungin with fluconazole in a randomized, double-blind, noninferiority trial of treatment for invasive candidiasis. Methods Adults with invasive candidiasis were randomly assigned to receive either intravenous anidulafungin or intravenous fluconazole ... Conclusions Anidulafungin was shown to be noninferior to fluconazole in the treatment of invasive candidiasis. (New England Journal of Medicine)
Natural cure could work May 22, 2007
Lowering your intake of white refined sugar may reduce your risk of yeast and fungal infections like athlete's foot, toenail fungus, jock itch and vaginal candidiasis. Drink water, as soda pop is loaded with sugar. (Shoals TimesDaily)
Diagnosis of invasive candidiasis by enzyme-linked immunosorbent assay using the N-terminal fragment of Candida albicans hyphal wall protein 1 Apr 22, 2007
The diagnosis of invasive candidiasis is difficult because there are no specific clinical manifestations of the disease and colonization and infection are difficult to distinguish. In the last decade, much effort has been made to develop reliable tests for rapid diagnosis of invasive candidiasis, but none of them have found widespread clinical use ... Antibodies against a recombinant N-terminal fragment of the Candida albicans germ tube-specific antigen hyphal wall protein 1 (Hwp1) generated in... (BioMed Central)
Bacterial vaginosis Apr 14, 2007
The term vaginitis suggests an infection associated with the presence of inflammatory cells (neutrophils), commonly seen in vulvovaginal candidiasis or Trichomonas vaginalis infections. Bacterial vaginosis is diagnosed by clinical symptoms and laboratory microscopic examination of vaginal fluids (Gram stain). (Suite101.com)
Scientific Results Presented At ECCMID Demonstrate Well-Differentiated Profile of Basilea's Two Phase III Anti-infective Compounds Apr 3, 2007
Basilea's antifungal isavuconazole for the potential treatment of invasive fungal infections is in phase III testing in a global trial program in patients with invasive candidiasis including candidemia and patients with proven or probable aspergillosis. New microbiological surveillance data relevant for the treatment of candidemia demonstrated isavuconazole's superior coverage of different candida species and most fluconazole-resistant isolates compared to other azole drugs (P1978). (Primezone Releases)
Researcher Finds New Way To Treat Devastating Fungal Infections Mar 6, 2007
He treated Candida albicans, often seen as esophageal candidiasis, an infection prevalent in HIV/AIDS and cancer patients receiving chemotherapy, and aspergillosis, an infection caused by aspergillus fumigatis, a family of common moulds that can cause symptoms ranging from cough to brain damage ... A form of invasive candidiasis called candidemia is the fourth most common bloodstream infection among hospitalized patients in the U.S. A survey conducted at CDCP found that candidemia occurs in... (Science Daily)
BDSI given OK to start human testing on drug delivery technology Feb 4, 2007
The first Bioral product to be tested is an oral version of Amphotericin B, an antifungicidal agent for treating infections such as esophageal candidiasis, an infection prevalent in HIV patients and many patients receiving cancer chemotherapy. Mark Sirgo, CEO of BDSI (Nasdaq: BDSI), said the human trials will begin in 2007 but the 15-employee company has yet to set an exact date. (Raleigh Triangle Business Journal, NC)
Sugar Diabetes Jan 30, 2007
Fatigue, reduction of energy levels, vision problems, constant thirst, muscle weakness, atherosclerosis, kidney failure, frequent urination, cystitis, candidiasis (fungus infections), tingling and numbness in hands and feet, foot infections, and high blood pressure are all symptoms of diabetes and should be checked if one or more are present. If sugar levels are not regulated they can cause symptomatic problems and complications with the eyes, muscles, kidneys and bladder and cardiovascular... (Suite101.com)
The New England Journal Of Medicine Publishes Two Landmark Studies Of NOXAFIL(R) (Posaconazole) in the Prevention of Invasive Fungal Infections Jan 25, 2007
NOXAFIL also was approved in the United States and EU in 2006 for the treatment of oropharyngeal candidiasis (OPC), a fungal infection of the mouth and throat, and in the EU in 2005 and Australia in 2006 for the treatment of certain IFIs in adult patients with disease that is refractory to or in patients who are intolerant of certain commonly used antifungal agents ... The product label should be consulted when other drugs are prescribed with NOXAFIL. In clinical studies of oropharyngeal... (PR Newswire)
Coping with HIV| Jan 11, 2007
Candidiasis, or thrush, is common in HIV-positive patients, and is an Aids-defining condition ... People with Aids are at risk of developing disseminated candidiasis, in which the fungus spreads through the body. (iAfrica.com)
Astellas Pharma US, Inc. Submits Supplemental New Drug Application For Antifungal Product MYCAMINE(R) Dec 27, 2006
In 2005, MYCAMINE received approval by the FDA for the treatment of patients with esophageal candidiasis and prophylaxis of Candida infection in patients undergoing hematopoietic stem cell transplantation. "Astellas has had a strong presence in the anti-fungal market for several years and continues to invest in discovering new ways to address the therapeutic needs of clinicians and their patients," said Yoshihiko Hatanaka, President and Chief Executive Officer, Astellas Pharma US, Inc. "With... (PR Newswire)
REFLECTION on World AIDS Day Dec 1, 2006
When the body has lost a significant number of immune cells or when there is a large number of HIV particles in your body and you experience an opportunistic infection, you have AIDS. Such infections include candidiasis of the esophagus, bronchi, trachea, or lungs; chronic cryptosporidiosis, disseminated or pulmonary histoplasmosis, Pneumoscystis carinii, or Kaposi's sarcoma. What are initial symptoms: A person does not need to look or feel sick to have HIV. However, up to 70 percent of the very... (SunHerald.com)
Noxafil(R) (Posaconazole) Oral Suspension Approved in European Union for Prevention of Invasive Fungal Infections Nov 9, 2006
Treatment of Oropharyngeal Candidiasis (OPC) Also Approved KENILWORTH, N.J., Nov. 9 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: ) today announced that the European Commission has granted marketing approval to NOXAFIL(R) (posaconazole) Oral Suspension for prophylaxis (prevention) of invasive fungal infections (IFIs) in the following patients at high risk of developing these infections: patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or... (PR Newswire)
Rare Infections After Medically Induced Abortions Likely Not Drug-related Nov 8, 2006
Since 2000, five women in North America who had medically induced abortions (MIAs) died from toxic shock caused by a Clostridium sordellii infection. This has led some people to question the safety of the combination of the drugs mifepristone and misoprostol frequently used in MIA procedures. (Science Daily)
The Straight Dope® Oct 20, 2006
Those with candidiasis and low ALDH activity (for genetic or pharmaceutical reasons) can exceed those levels. If that describes you, maybe you should think seriously about that skateboard. (City Pages)
Controlling Antibiotics And Antibiotic Resistance In Hospitals Oct 13, 2006
In one of the first national studies on guidelines that control antibiotics and antibiotic resistance in hospitals, researchers from the Indiana University School of Medicine, the Regenstrief Institute, Inc. and the Richard Roudebush Veterans Administration Medical Center report that hospitals that follow national guidelines on controlling antibiotic use have lower rates of antibiotic resistance. In a study published in the October issue of Infection Control and Hospital Epidemiology, the... (Science Daily)
Pediatric HIV: Oral Lesions Are Commonly Associated With The Disease Oct 9, 2006
There are many variations of the way lesions appear, but a few common types are: candidiasis, or thrush, a fungal yeast infection; salivary gland enlargement; herpes simplex virus; inflammation of the gingiva; and canker sores ... -- Candidiasis, commonly called yeast infection or thrush, is a fungal infection of any of the Candida species, of which Candida albicans is probably the most. (Science Daily)
Use Of Antibiotic To Treat Infectious Eye Disease Trachoma May Increase Risk For Reinfection Sep 29, 2006
Use of the antibiotic azithromycin to treat trachoma in Vietnam resulted in an increase in the risk of re-infections, according to a study in the September 27 issue of JAMA.. In 1995, the World Health Organization (WHO) first published data on global blindness and reported that 15 percent of cases were due to trachoma (a contagious bacterial eye disease in which scar tissue forms inside the eyelid and causes infection), making it the second major cause of blindness after cataract. (Science Daily)
Divas are for ever Sep 24, 2006
She has had pneumonia several times, a fractured back (twice), a brain tumour (benign), addictions to alcohol and prescription drugs, two hip replacements, candidiasis, osteoporosis. She also took overdoses on two occasions. (Times Online)
European Union's CHMP Adopts Positive Opinion for NOXAFIL(R) (posaconazole) Oral Suspension for Prevention of Invasive Fungal Infections Sep 22, 2006
Treatment of Oropharyngeal Candidiasis (OPC) Also Recommended for Approval KENILWORTH, N.J., Sept. 22 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: ) today reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive opinion recommending approval of NOXAFIL(R) (posaconazole) Oral Suspension for prophylaxis (prevention) of invasive fungal infections (IFIs) in the following patients at high risk of developing these... (PR Newswire)
'Wait-and-see' Approach For Treating Ear Infections Substantially Reduces Use Of Antibiotics Sep 22, 2006
Wait-and-see' Approach For Treating Ear Infections Substantially Reduces Use Of Antibiotics. For children with acute ear infections seen in an emergency department, giving parents the option of delaying use of antibiotics resulted in significantly lower use of antibiotics compared to parents who received a standard prescription, with little difference in the outcomes for the children, according to a study in the September 13 issue of JAMA.. (Science Daily)
Acute Vulvovaginitis Sep 21, 2006
Vulvovaginal Candidiasis ... Vulvovaginal Candidiasis. (New England Journal of Medicine)
- Andrew Whitley Sep 17, 2006
Irritable bowel syndrome, candidiasis and Crohn's disease all entered common parlance. Coeliac disease now affects one in a 100 people, other wheat intolerances probably more. (Guardian Unlimited)
Combo Drug Therapy Protects HIV-Positive Children Jul 19, 2006
Other infections that were down significantly included: dermatophyte infections, oral candidiasis, tuberculosis, mycobacterium avium, cytomegalovirus retinitis and pneumocystis jeroveci pneumonia. "The medications we use to treat HIV infections have very real benefits in terms of survival and in terms of reducing complications," said editorial author Dr. Joseph Harwell, an assistant professor of medicine in pediatrics at Brown Medical School in Providence, R.I. "I have not seen a child who is on... (Health-Finder)
Chronic Middle Ear Infections Linked To Resistant Biofilm Bacteria Jul 13, 2006
-- Candidiasis, commonly called yeast infection or thrush, is a fungal infection of any of the Candida species, of which Candida albicans is probably the most. . (Science Daily)
Basilea Presents Compelling Clinical and Preclinical Data on Its Novel Broad-Spectrum Antifungal BAL8557 Jun 27, 2006
Safety Results of Phase II Esophageal candidiasis Study ... -- A-565 / BAL8557 a Water-soluble Azole in a Phase II Double-blind Esophageal candidiasis Trial: Safety, QT Analysis, and Pharmacokinetics of three Different Dosing Regimens. (Primezone Releases)
It's all in his bread Jun 24, 2006
The doctor suspected candidiasis, a condition in which a common yeast called candida albicans, which normally lives in a healthy balance in the body, multiplies and travels to all parts of the body, including the digestive tract ... Bouwman began researching candidiasis, and with the help of his doctor, began a treatment program. (Echo Press)
Novartis bids $569 for UK firm Jun 8, 2006
NeuTec's most advanced product, Mycograb, is currently awaiting European approval for the treatment of invasive candidiasis -- a life-threatening form of thrush. It is also investigating using the medicine as a breast cancer treatment. (CNN International)
Toward A Less Expensive, More Convenient Treatment Of Gaucher's Disease May 30, 2006
(June 9, 2005) -- A bioadhesive tablet containing the antifungal drug miconazole is an effective and convenient means of treating oropharyngeal candidiasis, which is the most frequently occurring infection in head and. . (Science Daily)
Basilea gets US fast-track for antifungal May 2, 2006
In September last year Basilea reported positive phase II results on BAL8557 in the treatment of esophageal candidiasis. The safety profile of BAL8557 in those patients was observed to be similar to that of fluconazole. (ABC News -- Business)
Yeast Treatment May Affect Warfarin Therapy Mar 4, 2006
Fluconazole (brand name, Diflucan) is a common treatment for vaginal candidiasis, and is known to interact with a number of drugs, including warfarin -- which can give rise to serious bleeding complications -- according to the report in the medical journal Obstetrics and Gynecology. While a few studies have looked at the effect of several days of fluconazole therapy on bleeding risk in warfarin users, until now none had looked at the impact of a single dose. (MEDLINEplus)
Movers & Shakers Feb 18, 2006
4% gain after the company said it's received approval of Vusion, a steroid-free ointment for the treatment of diaper dermatitis complicated by candidiasis in infants 4 weeks and older, from the Food and Drug Administration. Barrier said Vusion is the only prescription product approved for the treatment of the condition in the U.S. The company expects the first shipment of the product to be in the second quarter. (CBS MarketWatch - Front Page)
Effect of prolonged HAART on oral colonization with Candida and candidiasis Jan 20, 2006
Progressive cell-mediated immunodeficiency with decrease of CD4+ lymphocyte count to less than or equal to 200 cells/mm3 is a major risk factor for colonization with Candida species and development of candidiasis. Oropharyngeal candidiasis may occur in up to 90% of human immunodeficiency virus (HIV)-infected patients during the course of the disease ... This study is to determine the effect of prolonged highly active antiretroviral therapy (HAART) on oropharyngeal colonization with Candida... (BioMed Central)
